RCM
PRTK

Rotella Capital Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Rotella Capital Management’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-1,629
Closed -$40K – 451
2014
Q3 		$40K Buy
+1,629
New +$42.5K 0.04% 260

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
RAM
Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Rotella Capital Management's PRTK Position: Q4 2014 in Review

Rotella Capital Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q4 2014, closing a stake of 1,629 shares — an estimated $40K sold.

Rotella Capital Management first reported a position in PRTK in Q3 2014 and held it in 1 quarter. The position peaked at $40K in Q3 2014. 37 funds tracked by Wall St. Rank hold PRTK as of Q4 2014.

  • Rotella Capital Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q4 2014 after selling out during the quarter.
  • Rotella Capital Management sold 1,629 Paratek Pharmaceuticals, Inc. shares in Q4 2014, an estimated $40K.
  • Rotella Capital Management first reported a position in Paratek Pharmaceuticals, Inc. in Q3 2014 and held it in 1 quarter.
  • Rotella Capital Management's Paratek Pharmaceuticals, Inc. position peaked at $40K in Q3 2014.
  • 37 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2014.

Based on Rotella Capital Management's 13F filing for Q4 2014, filed 17 Feb 2015.